We are pleased to announce the addition of Christian Dougherty to the Objective Capital Partners team. In his role as Managing Director of the Valuation Practice, Christian adds invaluable experience and successful leadership to our team of professionals. His world class ability to serve clients and deep access in our industries of focus make him an outstanding addition to OCP’s senior team. With a proven ability to deliver a portfolio of valuation services to clients from San Diego to New York, Chris further strengthens Objective Capital’s Valuation Practice.(more…)
Objective Capital Partners is pleased to announce the addition of Matthew Pelo to the OCP team. In his role as Vice President, Matt brings valuable strategic insights and finance expertise to OCP’s clients. His leadership experience and extensive work in the areas of Genomics and Technology make him an outstanding addition to OCP’s senior team and further strengthen OCP’s Life Sciences and Healthcare Practice Group. With a proven ability to achieve exceptional results, Matt further enhances OCP’s ability to deliver premium investment banking and advisory services to our valued clients.
Cautiously optimistic. That is the tone for the Healthcare and Life Sciences Sector as we head into 2019. Many of us who attended JPMorgan’s Healthcare conference earlier this year in San Francisco, CA, walked away feeling this tone. Despite the ongoing stock market volatility, continuing Affordable Care Act (ACA) challenges, ongoing evolution of regulations, reimbursement policies and delivery models, and risk of a rise in drug price rhetoric in the United States, many are maintaining an optimistic stance for increased growth and efficiency opportunities.
San Diego, CA and Los Angeles, CA, January 31, 2019 — NanoIVD, Inc., a privately-held company, working on advancing scientific discoveries and understanding of cancer and Alzheimer’s disease for the purpose of diagnosis and treatment, has retained Objective Capital Partners, a middle-market Investment Banking firm located in Southern California and focused on strategic advisory, mergers & acquisitions (M&A), capital financing and valuation services, as their financial advisor. Objective Capital Partners will seek to identify strategic partnerships and financial investors for NanoIVD to progress the development of their novel work.(more…)
Objective Capital Partners, a leading middle market investment banking firm, is pleased to announce that it served as the exclusive advisor to Everyone Counts, a leading online voting and election software company, on its sale to Votem, a leader in blockchain voting systems.(more…)
Objective Capital Partners has consistently been recognized as a leading investment banking firm specializing in M&A, capital raising, strategic partnerships, and valuations. With more than 500 advisory engagements, we are proud to serve the transaction needs of growth stage and mid-sized companies with enterprise values of up to $250 million.(more…)
This past week, David H. Crean, PhD, Managing Director and head of our Life Sciences and Healthcare Practice Group, spent time reviewing the >400 life science opportunities that were presented to him and our investment banking firm in 2017 in which entrepreneurs and business owners were looking for either capital financing, sell-side M&A, strategic advisory services or partnering/ licensing. Nearly invariably, each investment pitch lacked the complete and necessary material to tell the comprehensive story that would be compelling for an investor to write a check. These entrepreneurs are very smart and passionate about their mission but need to recognize and think like investors or strategic buyers. Investors see and hear many investment opportunities and you need to be differentiated and stand out from the masses.(more…)
This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.